GlassScriptPhysician profile
Matthew B Mote
NPI 1154623940
$2,791.74
in general payments reported to CMS, 2019-2025
31 companies · $526 in 2025
The $526 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $286 · 2020: $116 · 2021: $12.26 · 2022: $341 · 2023: $658 · 2024: $853 · 2025: $526.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,036.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,036.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $347.40 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $339.23 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $336.42 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $240.94 | 2019-2025 | |
| Glaxosmithkline, LLC. | $219.77 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $210.87 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $113.50 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $102.04 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $98.10 | 2022-2025 | Gardasil 9, Capvaxive, Gardasil |
| Astellas Pharma US INC | $86.65 | 2023-2025 | Veozah |
| Exact Sciences Corporation | $75.88 | 2023-2024 | Cologuard Collection Kit |
| Corcept Therapeutics | $60.01 | 2024-2025 | Korlym |
| Janssen Pharmaceuticals, INC | $57.04 | 2019-2024 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $48.47 | 2024-2025 | Opsumit, Uptravi |
| Abbott Laboratories | $44.04 | 2024 | Freestyle Libre 3 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $37.78 | 2022-2024 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $35.46 | 2024-2025 | Voquezna |
| Mylan Specialty L.P. | $34.96 | 2022-2024 | Yupelri |
| Kowa Pharmaceuticals America, INC. | $34.10 | 2022-2023 | Livalo, Seglentis |
| Otsuka America Pharmaceutical, INC. | $32.77 | 2024-2025 | Rexulti |
| Abbvie INC. | $32.74 | 2024 | |
| Currax Pharmaceuticals LLC | $29.34 | 2023-2025 | Contrave |
| Amgen INC. | $28.83 | 2024-2025 | Repatha, Otezla, Repatha |
| Idorsia Pharmaceuticals US INC | $28.62 | 2023 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.26 | 2019-2024 | Xifaxan, Trulance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.59 | 2024 | Caplyta |
| Biohaven Pharmaceutical Holding Company LTD. | $16.04 | 2022 | |
| Exeltis, USA INC. | $15.85 | 2022 | |
| Genentech USA, INC. | $14.26 | 2019 | |
| Boston Scientific Corporation | $13.79 | 2019 | |
| Amarin Pharma, INC. | $11.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Mote listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.